间歇性替唑胺对肺结核的杀菌效应研究
本研究在结核空心纤维系统模型中评估替唑胺的杀菌效应与剂量分割,采用人体样肺内药代动力学。结果显示替唑胺单药在42天内完全消除7.1 log10 CFU/mL结核分枝杆菌,每周一次方案与每日方案杀菌效果相当,EC80为游离药物0-24小时AUC/MIC比200,200 mg/日可使92%患者达到EC80。
要点
- 替唑胺在空心纤维模型中显示显著杀菌效应,42天完全消除7.1 log10 CFU/mL。
- 每周一次替唑胺方案杀菌效果与每日方案相当,EC80为游离AUC/MIC比200。
- 口服替唑胺200 mg/日可使92%患者达到EC80,且不抑制线粒体酶。
核心结论
- 替唑胺具有显著杀菌效应,值得在肺结核患者中进一步研究。
- 推荐200 mg/日或700 mg每周两次的替唑胺剂量用于患者测试,间歇方案可能比每日利奈唑胺更安全。
研究设计与样本
- 在结核空心纤维系统模型中进行42天替唑胺暴露-效应和剂量分割研究,采用人体样肺内药代动力学。
- 使用时间至阳性(TTP)和菌落形成单位(CFUs)检查细菌负荷,采用抑制性Sigmoid最大杀灭模型分析暴露-效应。
- 通过10000例患者蒙特卡洛实验确定达到EC80的最低剂量。
主要发现
- 替唑胺单药在最大效应时42天内完全消除7.1 log10 CFU/mL结核分枝杆菌,但TTP仍显示部分生长。
- 每周一次替唑胺方案杀菌效果与每日方案相当,EC80游离药物0-24小时AUC/MIC比为200。
- 口服替唑胺200 mg/日使92%的10000例患者达到EC80,药敏折点为MIC 0.5 mg/L。
- 200 mg/日剂量未达到与线粒体酶抑制相关的浓度。
关键数值与推荐
- EC80定义为介导80%最大杀灭的暴露量,游离药物0-24小时AUC/MIC比为200。
- 药敏折点为MIC 0.5 mg/L。
- 推荐测试剂量:200 mg/日或700 mg每周两次。
临床怎么用
- 替唑胺200 mg/日或700 mg每周两次可作为肺结核治疗的候选剂量进行临床测试。
- 间歇性替唑胺给药方案可能比每日利奈唑胺更安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Linezolid exhibits remarkable sterilizing effect in tuberculosis; however, a large proportion of patients develop serious adverse events. The congener tedizolid could have a better side-effect profile, but its sterilizing effect potential is unknown. METHODS: We performed a 42-day tedizolid exposure-effect and dose-fractionation study in the hollow fiber system model of tuberculosis for sterilizing effect, using human-like intrapulmonary pharmacokinetics. Bacterial burden was examined using time to positivity (TTP) and colony-forming units (CFUs). Exposure-effect was examined using the inhibitory sigmoid maximal kill model. The exposure mediating 80% of maximal kill (EC80) was defined as the target exposure, and the lowest dose to achieve EC80 was identified in 10000-patient Monte Carlo experiments. The dose was also examined for probability of attaining concentrations associated with mitochondrial enzyme inhibition. RESULTS: At maximal effect, tedizolid monotherapy totally eliminated 7.1 log10 CFU/mL Mycobacterium tuberculosis over 42 days; however, TTP still demonstrated some growth. Once-weekly tedizolid regimens killed as effectively as daily regimens, with an EC80 free drug 0- to 24-hour area under the concentration-time curve-to-minimum inhibitory concentration (MIC) ratio of 200. An oral tedizolid of 200 mg/day achieved the EC80 in 92% of 10000 patients. The susceptibility breakpoint was an MIC of 0.5 mg/L. The 200 mg/day dose did not achieve concentrations associated with mitochondrial enzyme inhibition. CONCLUSIONS: Tedizolid exhibits dramatic sterilizing effect and should be examined for pulmonary tuberculosis. A tedizolid dose of 200 mg/day or 700 mg twice a week is recommended for testing in patients; the intermittent tedizolid dosing schedule could be much safer than daily linezolid.
引用
- Srivastava S, Deshpande D, Nuermberger E, et al. The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis. Clin Infect Dis. 2018. PMID: 30496463. doi:10.1093/cid/ciy626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。